55661-71-7

Basic information

• Product Name: Quinazoline, 1,2,3,4-tetrahydro-2-phenyl-
• CAS NO: 55661-71-7
• Molecular Formula: C14H14N2
• Molecular Weight: 210.279
• Mol File: 55661-71-7.mol
• Article Data: 22

Chemical Properties

• CAS DataBase Reference: Quinazoline, 1,2,3,4-tetrahydro-2-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: Quinazoline, 1,2,3,4-tetrahydro-2-phenyl-(55661-71-7)
• EPA Substance Registry System: Quinazoline, 1,2,3,4-tetrahydro-2-phenyl-(55661-71-7)

Safety Data

• Hazardous Substances Data: 55661-71-7(Hazardous Substances Data)

Upstream product

• 1904-73-0 2-phenyl-3,4-dihydroquinazoline 
• 100-52-7 benzaldehyde 
• 4403-69-4 2-amino-1-benzylamine 
• 895771-34-3 N-(2-aminobenzyl)benzamide 
• 127896-76-8 N-(1-chlorobenzyl)pyridinium chloride 
• 121998-76-3 2-phenyl-2,3-dihydro-4(1H)-quinazolinone 
• 100-51-6 benzyl alcohol 
• 17901-93-8 benzaldehyde-d6 
• 1353000-46-0 2-aminobenzylamine-d2 

Downstream Products

• 1022-45-3 2-phenyl-4(3H)-quinazolinone 
• 1904-73-0 2-phenyl-3,4-dihydroquinazoline 
• 84570-72-9 N-(4-Nitro-phenyl)-2-(2-phenyl-1,4-dihydro-2H-quinazolin-3-yl)-propionamide 
• 84570-67-2 N-(4-Nitro-phenyl)-2-(2-phenyl-1,4-dihydro-2H-quinazolin-3-yl)-acetamide 
• 84570-70-7 N-(4-Bromo-phenyl)-2-(2-phenyl-1,4-dihydro-2H-quinazolin-3-yl)-propionamide 
• 84570-69-4 N-(4-Chloro-phenyl)-2-(2-phenyl-1,4-dihydro-2H-quinazolin-3-yl)-propionamide 
• 84570-71-8 2-(2-Phenyl-1,4-dihydro-2H-quinazolin-3-yl)-N-p-tolyl-propionamide 
• 84570-65-0 N-(4-Bromo-phenyl)-2-(2-phenyl-1,4-dihydro-2H-quinazolin-3-yl)-acetamide 
• 84570-64-9 N-(4-Chloro-phenyl)-2-(2-phenyl-1,4-dihydro-2H-quinazolin-3-yl)-acetamide 
• 84570-73-0 N-Phenyl-2-(2-phenyl-1,4-dihydro-2H-quinazolin-3-yl)-propionamide 
• 84570-66-1 2-(2-Phenyl-1,4-dihydro-2H-quinazolin-3-yl)-N-p-tolyl-acetamide 
• 84570-68-3 N-Phenyl-2-(2-phenyl-1,4-dihydro-2H-quinazolin-3-yl)-acetamide 
• 100-52-7 benzaldehyde 
• 4403-69-4 2-amino-1-benzylamine 

Relevant articles and documents

Palladium(ii): N, N, O -pincer type complex-mediated dehydrogenative coupling of alcohols to quinazolines

A new palladium(ii) N,N,O-pincer type complex-promoted one-pot cascade synthesis of quinazolines through the dehydrogenative coupling of easily available alcohols and 2-aminobenzylamine is reported. A distinct set of Pd(ii) complexes (1-2) was synthesized

Mixed crystalline phases and catalytic performance of OMS-2 based nanocomposites for one-pot synthesis of quinazolines with O2 as an oxidant

In this work, a series of sodium phosphotungstate modified manganese oxide octahedral molecular sieve (OMS-2) catalysts ([PW]-OMS-2) were developed, and their catalytic activities were investigated by one-pot synthesis of quinazolines from benzyl alcohol and 2-aminobenzylamine with O2 as green oxidant in dimethyl carbonate (DMC). TEM, XRD and EDS confirmed that sodium phosphotungstate decomposed into phosphotungstic acid and sodium tungstate in the doping process. Meanwhile, phosphotungstic acid attached and located at the surface of OMS-2 and W ions were successfully doped into the OMS-2 framework. For comparison, phosphotungstic acid/OMS-2 was prepared by simple wet impregnation method. The [PW]-OMS-2 is the most highly selective and effective over than phosphotungstic acid/OMS-2 and OMS-2 itself in the one-pot synthesis of quinazolines. It may be due to the synergetic effect of phosphotungstic acid and OMS-2, and successfully doping W into OMS-2 frameworks. Hence, this work provides a new environmentally-friendly and heterogeneous OMS-2 based nanocomposites and it may be put into practice to synthesize heterocyclic compounds.

Transcriptome analysis predicts mode of action of benzimidazole molecules against Staphylococcus aureus UAMS-1

Antimicrobial drug resistance is one of the most critical problems that plagued the human race in modern times. Discovery of novel antibiotics is important to counter this threat. Accordingly, herein we have reported the discovery of substituted benzimidazole class of molecules with antimicrobial property (specifically against Staphylococcus aureus). They were initially identified through a random screening and a novel catalytic synthetic strategy was utilized to access them. in vitro screening and phenotypic profiling revealed the antimicrobial nature. De novo transcriptome and gene analyses predicted the putative targets. This work provides a solid foundation for developing the benzimidazoles as a target specific antimicrobial preclinical candidate.